Psych Inc

Psych Inc is a San Francisco-based neurotechnology company developing objective biomarkers and digital cognitive assessment tools to optimize psychedelic-assisted therapy outcomes. The company leverages EEG-based neuroimaging technology to create quantifiable neurological metrics that track brain activity patterns and cognitive function before, during, and after psychedelic interventions. Their platform translates complex neural data into actionable insights that clinicians can use to predict treatment response, monitor patient progress, and make data-driven decisions about therapy protocols. By grounding psychedelic medicine in objective neuroscience, Psych Inc addresses a critical gap in the clinical measurement of these emerging therapeutic modalities.

The company recently closed a $4M seed funding round and is positioned at the intersection of two high-growth sectors: psychedelic-assisted psychiatry and digital biomarker innovation. This funding milestone reflects growing investor confidence in objective measurement tools for novel mental health treatments as the field moves toward clinical validation and regulatory approval. Psych Inc's timing is strategic, arriving as major academic medical centers and specialized clinics scale psychedelic therapy programs and regulators increasingly demand objective efficacy data to support therapy approval.

Psych Inc represents an important evolution in neurotech by bringing rigor and measurability to an emerging therapeutic paradigm that currently relies heavily on subjective clinical assessment. Their work demonstrates how EEG-based biomarkers can accelerate drug development cycles and improve patient outcomes in precision psychiatry. As psychedelic-assisted therapies advance through clinical trials and toward mainstream adoption, platforms that provide objective neurological endpoints will be essential infrastructure for practitioners, researchers, and regulators navigating this transformative period in mental health medicine.